CTLA4 and hepatocellular carcinoma: As single agent, nivolumab demonstrated no improvement is survival compared with sorafenib; the combination of nivolumab and ipilimumab (CTLA-4 inhibitor) was administered at different doses and intervals to patients with advanced HCC previously treated with sorafenib (Yau et al., 2022).